Jim Simons’s Axsome Therapeutics AXSM Stock Holding History

Jim Simons’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.8M	Sell	164,300 -5,700	-3%	-$985K	0.04%	526
2025 Q4	$31M	Buy	170,000 +20,000	+13%	+$2.79M	0.05%	438
2025 Q3	$18.2M	Buy	150,000 +11,300	+8%	+$1.27M	0.02%	769
2025 Q2	$14.5M	Buy	138,700 +4,300	+3%	+$455K	0.02%	866
2025 Q1	$15.7M	Buy	+134,400	New	+$15.3M	0.02%	769
2020 Q3	–	Sell	-66,400	Closed	-$5.46M	–	3368
2020 Q2	$5.46M	Buy	66,400 +14,300	+27%	+$1.1M	﹤0.01%	1590
2020 Q1	$3.06M	Buy	52,100 +1,330	+3%	+$108K	﹤0.01%	1833
2019 Q4	$5.25M	Buy	+50,770	New	+$2.05M	﹤0.01%	1821
2019 Q3	–	Sell	-247,200	Closed	-$6.37M	–	3422
2019 Q2	$6.37M	Buy	+247,200	New	+$4.95M	0.01%	1680
2019 Q1	–	Sell	-15,110	Closed	-$43K	–	3443
2018 Q4	$43K	Buy	+15,110	New	+$49.7K	﹤0.01%	3296
2018 Q1	–	Sell	-48,400	Closed	-$271K	–	3363
2017 Q4	$271K	Buy	+48,400	New	+$244K	﹤0.01%	3049

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jim Simons's AXSM Position: Q1 2026 in Review

Jim Simons reduced its Axsome Therapeutics (AXSM) stake by 3.4% in Q1 2026, selling an estimated $985K and leaving 164,300 shares worth $27.8M. The position accounts for 0.04% of the portfolio, ranked #526.

Jim Simons first reported a position in AXSM in Q4 2017 and has held it in 11 quarters since. The position peaked at $31M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Jim Simons held 164,300 shares of Axsome Therapeutics worth $27.8M as of Q1 2026.
Jim Simons sold 5,700 Axsome Therapeutics shares in Q1 2026, an estimated $985K.
Axsome Therapeutics made up 0.04% of Jim Simons's portfolio in Q1 2026, its #526 holding.
Jim Simons first reported a position in Axsome Therapeutics in Q4 2017 and has held it in 11 quarters since.
Jim Simons's Axsome Therapeutics position peaked at $31M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.